The prognostic value of apoptotic and proliferative markers in breast cancer
- 6 November 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 142 (2), 323-339
- https://doi.org/10.1007/s10549-013-2748-y
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- New Insight into Ki67 Expression at the Invasive Front in Breast CancerPLOS ONE, 2013
- Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K–AKT, Wnt/β-catenin and P53 pathway activationGynecologic Oncology, 2012
- Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancersAnnals Of Oncology, 2012
- Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancerBritish Journal of Cancer, 2011
- Current and emerging biomarkers in breast cancer: prognosis and predictionEndocrine-Related Cancer, 2010
- COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patientsBreast Cancer Research and Treatment, 2010
- The Predictive Value of HLA Class I Tumor Cell Expression and Presence of Intratumoral Tregs for Chemotherapy in Patients with Early Breast CancerClinical Cancer Research, 2010
- Validation study of the prognostic value of cyclin-dependent kinase (CDK)-based risk in Caucasian breast cancer patientsBritish Journal of Cancer, 2009
- REporting recommendations for tumor MARKer prognostic studies (REMARK)Breast Cancer Research and Treatment, 2006
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976